DeepMed Research

UCB BIOPHARMA SRL

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study Participants

Phase 1

Completed

Conditions: Healthy Study Participants

Interventions: Drug: brivaracetam

First Posted Date: 2022-04-07

Last Posted Date: 2024-01-05

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 24

Registration Number: NCT05315947

Locations: 🇯🇵
EP0110 1, Sumida-ku, Japan

A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants

Phase 1

Completed

Conditions: Healthy Study Participants

Interventions: Drug: bimekizumab

First Posted Date: 2022-03-23

Last Posted Date: 2025-04-10

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 121

Registration Number: NCT05292131

Locations: 🇺🇸
UP0119 2, Glendale, California, United States
🇩🇪
UP0119 1, Berlin, Germany

A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)

Phase 1

Active, not recruiting

Conditions: Atopic Dermatitis

Interventions: Biological: UCB1381
Drug: Placebo

First Posted Date: 2022-03-14

Last Posted Date: 2025-05-18

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 273

Registration Number: NCT05277571

Locations: 🇺🇸
Up0110 125, Beverly Hills, California, United States
🇺🇸
Up0110 101, Glendale, California, United States
🇺🇸
Up0110 121, Northridge, California, United States

and more 13 locations

A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Phase 3

Completed

Conditions: Childhood Absence Epilepsy
Juvenile Absence Epilepsy

Interventions: Drug: Brivaracetam Film-coated tablet
Drug: Brivaracetam oral solution

First Posted Date: 2021-11-05

Last Posted Date: 2025-04-03

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 84

Registration Number: NCT05109234

Locations: 🇺🇸
Ep0132 115, Birmingham, Alabama, United States
🇮🇹
Ep0132 320, Pavia, Italy
🇮🇹
Ep0132 322, Roma, Italy

and more 21 locations

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

Phase 3

Recruiting

Conditions: Stereotypical Prolonged Seizures

Interventions: Drug: Staccato alprazolam
Other: Placebo

First Posted Date: 2021-10-14

Last Posted Date: 2025-04-25

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 350

Registration Number: NCT05077904

Locations: 🇯🇵
Ep0162 20316, Sapporo, Japan
🇯🇵
Ep0162 20070, Shinjuku-ku, Japan
🇯🇵
Ep0162 20297, Shinjuku-ku, Japan

and more 159 locations

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

Phase 3

Conditions: Stereotypical Prolonged Seizures

Interventions: Drug: Staccato alprazolam

First Posted Date: 2021-10-13

Last Posted Date: 2025-04-25

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 300

Registration Number: NCT05076617

Locations: 🇺🇸
Ep0165 50511, Pittsburgh, Pennsylvania, United States
🇺🇸
Ep0165 50491, Pittsburgh, Pennsylvania, United States
🇺🇸
Ep0165 50513, Memphis, Tennessee, United States

and more 135 locations

A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis

Phase 3

Completed

Conditions: Osteoporosis

Interventions: Drug: Romosozumab
Drug: Placebo

First Posted Date: 2021-10-05

Last Posted Date: 2024-12-05

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 327

Registration Number: NCT05067335

Locations: 🇨🇳
Op0002 20199, Rui'an, China
🇨🇳
Op0002 20130, Beijing, China
🇨🇳
Op0002 20117, Guangzhou, China

and more 27 locations

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)

Phase 3

Recruiting

Conditions: Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)

Interventions: Other: Placebo
Drug: Rozanolixizumab

First Posted Date: 2021-09-30

Last Posted Date: 2025-04-25

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 104

Registration Number: NCT05063162

Locations: 🇰🇷
Mog001 20226, Goyang-si, Korea, Republic of
🇰🇷
Mog001 20104, Seoul, Korea, Republic of
🇲🇽
Mog001 50485, Ciudad de Mexico, Mexico

and more 74 locations

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Moderate to Severe Plaque Psoriasis

Interventions: Other: Placebo
Drug: bimekizumab

First Posted Date: 2021-08-25

Last Posted Date: 2025-03-18

Lead Sponsor: UCB Biopharma SRL

Target Recruit Count: 47

Registration Number: NCT05020249

Locations: 🇰🇷
Ps0032 20211, Bucheon-si, Korea, Republic of
🇰🇷
Ps0032 20210, Seongnam-si, Korea, Republic of
🇰🇷
Ps0032 20104, Seoul, Korea, Republic of

and more 6 locations

CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

First Posted Date: 2021-08-20

Last Posted Date: 2024-01-25

Lead Sponsor: UCB Biopharma SRL

Registration Number: NCT05014724

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy